Related Experiment Videos
Felbamate-associated fatal acute hepatic necrosis
M G O'Neil1, C S Perdun, M B Wilson
1Department of Pharmacy Practice, College of Medicine, Medical University of South Carolina, Charleston, USA.
Neurology
|May 1, 1996
Summary
Felbamate (Felbamate) can cause severe liver damage, including fatal hepatic necrosis. This risk necessitates careful monitoring of patients undergoing felbamate therapy for seizures.
Area of Science:
- Hepatology
- Neurology
- Pharmacology
Background:
- Felbamate is an anticonvulsant medication used to treat epilepsy.
- Hepatic toxicity is a known, albeit rare, adverse effect associated with felbamate use.
- The Food and Drug Administration (FDA) has collected data on adverse events related to felbamate.
Observation:
- This report details a specific case of massive acute hepatic necrosis.
- The patient initiated felbamate therapy for generalized tonic-clonic seizures.
- The severe liver injury and subsequent death occurred within 40 days of starting the medication.
Findings:
- The study presents the clinical presentation and histopathological findings of a fatal case of felbamate-induced liver injury.
- Analysis of FDA data reveals 36 collected cases of hepatic toxicity linked to felbamate.
- Five fatalities have been reported among these cases, highlighting the potential severity.
Implications:
- The findings underscore the critical need for vigilant liver function monitoring in patients prescribed felbamate.
- This case adds to the evidence base regarding the hepatotoxic potential of felbamate.
- Healthcare providers should carefully weigh the risks and benefits of felbamate, especially in patients with pre-existing liver conditions.